中国肺癌杂志2012，Vol.15Issue(3)：164-171,8.DOI:10.3779/j.issn.1009-3419.2012.03.06
晚期肺腺癌患者一线化疗后T淋巴细胞亚群变化及临床意义
Clinical Significance of T Lymphocyte Subset Changes After First Line Chemotherapy in Peripheral Blood from Patients with Advanced Stage Adenocarcinoma Cell Lung Cancer
摘要
Abstract
Background and objective The immune function disorder relates closely to the occurrence, metastasis, and prognosis of cancer. T lymphocyte subsets take an important role in immune function. We identified the dynamic changes of the immune system by investigating the levels of T lymphocyte subsets in peripheral blood of lung cancer patients with advanced stage adenocarcinoma undergoing first line chemotherapy. The results aided the search for rational chemo-immunotherapy strategies in lung cancer treatment. Methods Samples from 49 patients with pathologically demonstrated advanced stage adenocarcinoma cell lung cancer were compared with those from 33 healthy donors. Subsequently, the patients were separately treated with Docetaxol-based or Pemetrexed-based therapy. Peripheral blood samples at different time points after therapy were analyzed by flowcytometry. The lymphocyte subsets of the total lymphocytes were compared. Independent sample t test was used for the quantitative data analysis. Results The percentage of CD3+, CD3+CD4+, CD4+CD25+ cells of the lung cancer patients significantly varied from those of the healthy donors, the P values are 0.012, 0.034 and 0.006 separately. The CD3+ and CD3+CD4+ levels increased significantly on the 4th and 7+-10+ day post-chemotherapy, which return to normal levels on the 21th day. The CD3+ level increased significantly both in the treatment group on all time points, while the CD3+, CD3+CD4+, CD47CD8+ levels significantly increased and the CD3+CD8+, CD8+CD28+ levels significantly decreased on the 4th day in Pemetrexed group. The CD3+CD4+ levels increased significantly on the 4th and 7th-10th day and the CD3+CD8+, CD8+CD28 levels decreased on the 4th day in partial response group. Conclusion The immune function of advanced stage ad-enocarcinoma cell lung cancer patients was evidently suppressed, and was restored at the 4th day, followed by a reduction at the 21st day after chemotherapy. On the 4th day, Pemetrexed showed better effect on the immune system. The change of immune system post-chemotherapy could be related with the prognosis.关键词
肺肿瘤/多西他赛/培美曲塞/T淋巴细胞亚群/流式细胞仪Key words
Lung neoplasms/ Docetaxol/ Pemetrexed/ T lymphocyte subsets/ Flowcytometry分类
医药卫生引用本文复制引用
燕翔,赵晓,焦顺昌,孙胜杰,吴亮亮,吴志勇..晚期肺腺癌患者一线化疗后T淋巴细胞亚群变化及临床意义[J].中国肺癌杂志,2012,15(3):164-171,8.基金项目
本研究受国家科技部课题项目基金(No.2009BAI86B05)资助 （No.2009BAI86B05）
